Telemedicine After the Hype: What African Health Platforms Have Actually Achieved

A decade ago, “telemedicine” was the word every African tech pitch deck reached for. A doctor in your pocket, healthcare leapfrogging broken infrastructure, a continent of 1.4 billion people finally getting the clinician access it lacked. The pandemic further accelerated that narrative: a 2022 World Health Organisation report noted that telehealth consultations in several African countries increased by 300-500% between 2019 and 2021.

Five or six years on, it’s worth asking a quieter question. Not whether telemedicine sounded good, but what it actually built.

From Consultation Apps to Integrated Care

The clearest lesson from Nigeria’s health tech sector is that pure teleconsultation, on its own, rarely survives as a business. Reliance Health is the most cited example. Its founders launched Kangpe in 2015, a “doctor in your pocket” app built around remote consultations. A year into running the business, realising how early the market was and the systemic follow-up gaps that existed, they pivoted from Femi Kuti’s own account. The problem wasn’t getting a patient to a doctor by chat. It was what happened after: if that doctor recommended an X-ray or a referral, there was no system to carry the patient through it.

That gap produced Reliance HMO, an insurance-and-care bundle that now blends direct clinics, drug delivery, and a network of partner hospitals with its original telemedicine layer. The shift wasn’t cosmetic. It reflected something the sector had to learn the hard way: a video call with a doctor is a feature, not a health system.

Helium Health followed a similar logic from a different angle. Rather than build patient-facing consultations as its core product, it went after hospital infrastructure: electronic medical records, billing, and lab workflows with HeliumDoc, its telemedicine and doctor-booking layer, sitting on top. According to reporting from TC Insights, Helium Health has digitised records for over 1 million patients and disbursed more than $10 million in loans to healthcare facilities through its financing arm. That’s a modest number set against Nigeria’s roughly 40,000 health facilities, but it is a real, auditable achievement, not a projection.

What the Money Actually Rewarded

Funding data tells a similar story about where value settled. Reliance Health’s 2022 Series B, at $40 million, was the largest round of its kind in African health tech at the time, led by General Atlantic. But the broader capital trend since then has moved away from consultation apps and toward what one analysis called “deep-tier infrastructure”, EMRs, pharmacy logistics, drug-supply authentication, and insurance rails, rather than the video-call layer itself.

Pharmacy-tech and supply-chain companies such as mPharma, which operates across Ghana, Nigeria, Kenya, Rwanda, and Zambia, captured nearly 40 percent of total African health-sector funding in recent years, more than pure telemedicine plays managed on their own. That is a meaningful signal. Investors initially bet on access, getting a consultation with someone who couldn’t reach a doctor. The money has followed the parts of the system that determine whether that consultation leads anywhere: the drugs, the records, the financing.

Counterfeit medicine is one place where this shows up concretely. Companies like DrugStoc and RxAll are using data-driven logistics and AI to address Nigeria’s roughly 30 percent counterfeit medicine problem, with RxAll’s scanner reportedly detecting fake drugs at close to 95 percent accuracy. None of that touches a teleconsultation screen, but it’s arguably closer to solving the actual crisis in care quality than remote diagnosis is.

Adoption Remains Deeply Uneven

Outside Nigeria, the picture diverges by region rather than converging into one continental story. South Africa has the highest telemedicine adoption rate, concentrated in specialist teleconsultations and chronic disease management, while Kenya leads in mobile-health integration for maternal health and HIV care. Kenya’s regulatory environment has helped: its 2023 Digital Health Act gave the sector a legal framework for data protection and interoperability that Nigeria still largely lacks.

The infrastructure constraints that limited telemedicine’s promise in the first place haven’t disappeared either. Rural connectivity, device costs, and clinician shortages remain binding constraints on how far remote consultation can travel. Nigeria’s own doctor-to-patient ratio, at roughly one doctor per 3,474 people against a WHO recommendation of one per 600, means telemedicine platforms are often connecting patients to a genuinely scarce resource rather than an underused one. A booking app doesn’t create more doctors.

What This Adds Up To

The honest assessment is that telemedicine in Africa did not fail, but it also did not become the standalone category its early boosters imagined. It became a feature, often a useful one, embedded inside insurance products, hospital software, and pharmacy networks that had to solve harder logistical problems to survive. Telemedicine still accounted for nearly half of all healthtech deal volume in 2023, but deal count and durable impact are not the same measure.

For Nigerian founders and investors, the lesson sitting underneath Reliance Health’s pivot and Helium Health’s infrastructure bet is the same one: a consultation is only valuable if the system around it can act on what the doctor says. The platforms that have lasted are the ones that built that system, not just the interface to reach it.